Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Nektar Therapeutics, Alkermes and Roche are among the companies with new solutions for more safely targeting an old cytokine well validated in cancer immunotherapy. Top execs explain how and why.
You may also be interested in...
Roche is paying $250m up front to buy Good Therapeutics, which will launch a new company, Bonum Therapeutics, to explore its platform technology for targets other than interleukin-2.
On the heels of clinical failures for Nektar’s pegylated IL-2 candidate bempeg, Alkermes’ CEO argued its high-dose IL-2 for cancer is well differentiated during earnings call. Schizophrenia drug Lybalvi posted solid first full-quarter revenue, prescription numbers.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames